Kynamro
FDA Approves New Kynamro for Inherited Cholesterol Disorder »
"The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemi"...
Read the FDA Approves New Kynamro for Inherited Cholesterol Disorder article »
Kynamro
OVERDOSE
There have been no reports of overdose with KYNAMRO treatment. In clinical trials, patients receiving higher doses of KYNAMRO (300 mg and 400 mg once weekly for 13 weeks) experienced adverse reactions similar to the adverse reactions experienced by patients receiving treatment with 200 mg once weekly but at slightly higher rates and greater severity. Liver-related tests should be monitored.Although there is no information on the effect of hemodialysis in treating an overdose with mipomersen, hemodialysis is unlikely to be useful in overdose management since mipomersen is highly bound to plasma proteins.
CONTRAINDICATIONS
KYNAMRO is contraindicated in the following conditions:
- Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]
- Patients with a known hypersensitivity to any component of this product [see ADVERSE REACTIONS].
Last reviewed on RxList: 2/8/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Kynamro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cholesterol Management
Tips to keep it under control.
Updated & New
